EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction

Rina Hayashi, Saori Takamura iD, Tomoo Fukuda

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.70241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Rina Hayashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Azetidines, Pyrazoles, Sulfonamides, Alopecia Areata. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baricitinib and ritlecitinib are newly approved systemic Janus kinase (JAK) inhibitors for severe, refractory alopecia areata (AA). Although clinical trials have demonstrated their efficacy, real‐world evidence remains limited, particularly regarding predictors of response and outcomes following treatment interruption or dose tapering. To evaluate the real‐world effectiveness and safety of baricitinib and ritlecitinib in adults with refractory AA, and to identify factors associated with treatment response and relapse. We retrospectively reviewed 65 adults with refractory AA treated at a tertiary center (baricitinib 4 mg/day, n = 50; ritlecitinib 50 mg/day, n = 15). Scalp regrowth was evaluated using the Severity of Alopecia Tool (SALT) up to Week 52, with response defined as SALT ≤ 20 (≥ 80% scalp coverage). Predictors of Week 36 response were assessed in the baricitinib cohort using multivariable logistic regression. Relapse outcomes after treatment discontinuation or dose reduction were documented with extended follow‐up. Adverse events (AEs) were recorded. At Week 36, 42% of patients receiving baricitinib achieved SALT ≤ 20, comparable to the ritlecitinib group (41.7%). In the baricitinib cohort, disease duration < 2 years and baseline eyebrow loss (ClinRO score 3) independently predicted Week 36 response ( p < 0.05). All four responders who discontinued baricitinib relapsed (mean 14.7 weeks). Among 13 patients who reduced the dose to 2 mg/day, relapse occurred in 6/12 evaluable cases (mean 24.2 weeks). Most AEs were mild, and no serious events occurred. Baricitinib demonstrated meaningful real‐world efficacy, particularly in patients with shorter disease duration and baseline eyebrow involvement. Relapse was common after treatment cessation or dose tapering, supporting the need for close monitoring for approximately 3 months after discontinuation and at least 6 months following dose reduction. These findings may inform patient selection and long‐term treatment planning, and highlight the importance of further prospective studies to optimize JAK inhibitor management in AA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesPyrazolesSulfonamidesAlopecia AreataJanus Kinase InhibitorsHumansFemaleRetrospective StudiesRecurrencePurinesAdultMaleTreatment OutcomeMiddle AgedTreatment InterruptionDrug TaperingSeverity of Illness Index

Stichwörter der Autor:innen

ClinROJAK inhibitorSALT scorealopecia areatabaricitinibritlecitinib

Substanzen

baricitinibAzetidinesPyrazolesSulfonamidesPurinesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

ORCID-Profile: Saori Takamura

Zitieren

APA

Hayashi, R., Takamura, S., & Fukuda, T. (2026). Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70241

Vancouver

Hayashi R, Takamura S, Fukuda T. Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70241

BibTeX
@article{Hayashi2026,
  author = {Hayashi, Rina and Takamura, Saori and Fukuda, Tomoo},
  title = {Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.70241}
}
Kostenlos starten →